Galmed Pharmaceuticals (GLMD)

• Market cap: $2.78M
• 1 day: -5.08%
• 5 days: -11.11%
• 1 month: -33.33%
• 3 months: -43.43%
• 6 months: -59.12%
• Year to date: -49.40%
• 1 year: -61.02%
• 5 years: -99.73%
• 10 years: -99.90%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Employees: 8

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

273% more capital invested

Capital invested by funds: $38.3K [Q3] → $143K (+$105K) [Q4]

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

20% more funds holding

Funds holding: 10 [Q3] → 12 (+2) [Q4]

2.59% more ownership

Funds ownership: 0.37% [Q3] → 2.97% (+2.59%) [Q4]